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ABSTRACT 
Objective:  Traumatic brain injury (TBI) is the number one cause of death under 44 years of age; in spite of this 
fact, there is no standard available pharmacological agent for the treatment of brain injury. It has a poor 
prognosis when misdiagnosed or a delayed treatment can lead to significant morbidity. We evaluated the 
effectiveness of magnesium sulphate treatment for the management and outcome of TBI. 
Material and Methods:  The prospective cases (n = 112) of TBI were included from Department of Neurosurgery, 
Shaikh Zayed Hospital, Lahore. Patients were split into two groups. Magnesium sulphate treatment group (n = 
56) and placebo group (n = 56). Detailed history of patients was taken along with comprehensive examinations 
with CT scans.56 TBI patients were given standard treatment plus magnesium sulphate and remaining 56 patients 
received just standard treatment. 
Results:  Mean age of the magnesium supplement therapy group was 36.83 ± 13.45 years while in the placebo 
group was 33.64 ± 12.88 years). Majority 28 (67.9%) were male in the magnesium sulphate group while 37 
(66.1%) were in the placebo group. Mean duration passed between hospital presentation and traumatic brain 
injury was 4.98 ± 2.32 hours in the magnesium sulphate group while it was 5.05 ± 2.48 in the placebo group. 
Mean Glasgow outcome score was 3.57 ± 1.33 in the magnesium sulphate group while 2.78 ± 1.23 in the placebo 
group and this difference was statistically significant. 
Conclusion:  There is significant improvement in GOS after magnesium sulphate therapy in patients with 
traumatic brain injury versus placebo group as noted in the results. 
Keywords:  Glasgow Outcome Score, Traumatic Brain Injury. 
 
INTRODUCTION 
An external force when comes in contact to the head 
or body causes central nervous system dysfunction and 
damage that results in injury to the brain (TBI); there 
are several scales available to quantify the TBI. The 
scales which are routinely used for assessment include 
the Glasgow Coma Scale (GCS) score and the time 
period of loss of consciousness or post traumatic 
amnesia.
1
 
 Severe traumatic brain injury (TBI) is a leading
cause of morbidity and mortality worldwide.
2
 TBI 
leads to  amnesia , loss of consciousness, paralysis, 
and even death; the average age of patients with brain 
injury  ranged from 27 to 59.67 years.
3
 The overall 
mild: moderate: severe ratio was 55: 27.7: 17.3 based 
on Glasgow Coma Scale (GCS). Asia ranked highest 
in percentage of Motor vehicle related TBIs. The 
percentage of fall and work related TBIs was highest.
3
 
 The number one cause of death under 44 years of 
age is TBI; in spite of this fact, there is no standard 
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available pharmacological agent for the treatment of 
brain injury. Medical management of patients with 
TBI is part of pre hospital triage. The aim of the 
treatment is to protect the brain from damage that 
occurs later (secondary brain insult).
4
 
 In the early phase of TBI, the excitotoxicity leads 
to necrosis, apoptosis, necroptosis, autophagy, or 
pyroptosis. Excitotoxic events and their relationship to 
neuronal death pathways in TBI has been extensively 
researched. Even then, after 45 years of research most 
therapies against excitotoxic events have not been 
effective clinically. There are very few options 
available to improve clinical outcomes after traumatic 
brain injury in spite of many years of research.
5
 
 With reference to various researches, magnesium 
sulfate administered after a brain injury (diffuse axonal 
injury) has proved to be a useful protective agent for 
central nervous system. In a research significant 
improvement was noticed in Glasgow outcome scale 
after acute magnesium sulphate therapy in patients 
with TBI at 3 months.
6
 
 In another study, patients admitted within one hour 
after severe brain injury who fulfill the inclusion 
standards were selected with random sampling. They 
were divided into two groups. 
 
Dose 
Patients were given a bolus dose of fifty mg/kg 
magnesium sulfate and then after every six hours, fifty 
mg/kg of MgSO4 was given up to twenty four hours 
after the brain injury. 
 The outcome was assessed by Glasgow Coma 
Scale (GCS) score, mortality, and motor function 
scores which were checked up to two months after 
TBI. There was statistically significant improvement 
of GCS score at two months after trauma in patients 
who were given Magnesium Sulphate.
7
 There was also 
improvement in the Motor function scores of patients 
who were given MgSO4. Although, this was not 
statistically significant (P equal to 0.51). Several 
studies have shown around 50% fall in brain free 
magnesium levels within hours after TBI. Clinical 
outcome is significantly improved when magnesium 
levels are restored back to baseline with various 
pharmacological approaches available.
7
 
 In a study done by Ling Zhao and others, there 
was higher GCS and significant lower GOS in MST 
(magnesium sulphate therapy) group as compared to 
placebo group. GCS scores on 3
rd
 day in the 
Magnesium sulphate therapy group (7.39 ± 2.07 with 
MgSO4 and 6.23 ± 2.29 without MgSO4). The mean 
Glasgow outcome score was significantly lower in the 
MgSO4 group at discharge and one month post 
discharge.
8
 
 A current meta-analysis of existing randomized 
controlled trials suggested that magnesium sulfate 
therapy is a useful agent in improving the Glasgow 
Outcome Scale and Glasgow Coma Scale scores, this 
is an encouraging data for TBI treatment.
9-10-11
 
 Magnesium has neuro protective role through 
various mechanisms, including NMDA receptor 
blockade, vascular smooth muscle relaxation, 
inhibition of excitatory neurotransmitter release and 
blockade of calcium channels.
12-13-14
 
 The aim of the study was to determine mean GCS 
and Glasgow outcome score in patients with traumatic 
brain injury after magnesium sulphate therapy. We 
designed this study to test the notion that treating a 
traumatic brain injury in patients with magnesium 
would improve outcome in short and long term after 
trauma. It will be a useful addition to the community 
knowledge. Data can be used by the care providers in 
investigating the problem and its management. 
 
MATERIAL AND METHODS 
Study Setting 
The study design was quasi experimental. This study 
was conducted in the Department of Neurosurgery at 
Sheikh Zayed Hospital, Lahore from May 2018 to July 
2019. We enrolled 112 patients who were presented 
with traumatic brain injury (TBI). They were divided 
into two groups; 56 patients in Magnesium sulphate 
group and 56 patients in the placebo group. Informed 
consents were taken from all patients or their 
attendants conformed to institutional ethical standards. 
 
Sampling Technique 
Patients were selected on the basis of non-probability 
consecutive sampling. Patients background 
information and clinical presentations were recorded. 
Patients were evaluated consisting of a detailed 
history, physical examination (history of LOC, ENT 
bleed, fits, vomiting, antegrade and retrograde 
amnesia). 
 
Inclusion Criteria 
We included patients of both genders with traumatic 
brain injury with age between 18 – 70 years who gave 
consent. 
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Exclusion Criteria 
We excluded pregnant women, children less than 18 
years of age, patients with poly trauma, patients with 
significant metabolic diseases (CRF, CCF etc) and 
those patients who did not give consent. 
 
Clinical Information 
All patients had undergone a CT scan (brain plain). 
The routine lab tests were conducted for CBC, 
coagulation profile, PT, APTT, renal and liver profiles 
(LFTs, RFTs) and other relevant tests for the 
stabilization for surgical intervention. 56 TBI patients 
were given standard treatment plus magnesium 
sulphate and remaining 56 patients received just 
standard treatment. 
 
Treatments of TBI 
The regular mode of treatment for TBI was that they 
received standard protocol treatment(patient is 
managed according to brain trauma guidelines, N.G/ 
Foleys passed, intravenous fluids, Mannitol infusion, 
antibiotics, nutrition, antiepileptic drugs as required, 
surgery if indicated) and along with this patients were 
given magnesium sulphate as an add on therapy. Blood 
samples for serum magnesium levels drawn on two 
occasions, at the time of admission and on the 3
rd
 day. 
Treatment guidelines consisted of an initial loading 
dose of 50 mg/kg magnesium sulfate and then 15 
mg/kg T.D.S up to 48 hours after the trauma. All the 
variables to be studied, including socio-demographic 
data like name, age, sex and address was collected. 
The clinical outcome was evaluated by using GOS (at 
1 month). 
 
Data Analysis 
Data analysis was performed in SPSS (v.22.0, IBM 
Corporation) software. Categorical variables like 
gender were described as frequencies and percentages. 
Quantitative variables like age, weight, height, was 
described as mean +/- standard deviation. The 
continuous variable like serum Magnesium levels and 
age was presented in the form of mean and S.D. 
Qualitative variable like gender and grades of Glasgow 
Outcome Scale, was presented in the form of 
frequency and percentages. Data was stratified by age 
and gender with regard to outcome variable, i.e., 
Glasgow outcome score. A t test was used to compare 
the means of parameters between the groups. A 
p value ≤ 0.05 was considered as significant. 
RESULTS 
There were 112 patients with primary brain trauma 
enrolled in the Neurosurgery Department of Shaikh 
Zayed Hospital, Lahore. Patients were split into two 
groups (n = 56) Magnesium sulfate group and (n = 56) 
placebo group. 
 
Age Incidence 
Mean age of the magnesium supplement therapy group 
was 36.8 years, while in the placebo group was 33.6 
years (Table 1). 
 
Table 1: Distribution of the Mean Age in the Study Groups. 
 
 Group of Treatment Mean 
Std. 
Deviation 
Age of 
patients 
Magnesium Supplement 
therapy 
36.83 13.45 
Placebo therapy 33.64 12.88 
 
Gender Distribution 
Table 2 shows that the majority were male, 38 
(67.9%) in the magnesium sulfate group while 37 
(66.1%) were in the placebo group. 
 
Table 2:  Distribution of the Gender in the Study groups. 
 
  
Gender of Patients 
 Total 
 Male  Female 
Group of 
treatment 
Magnesium 
Supplement therapy 
38 18 56 
67.9% 32.1% 100.0% 
Placebo therapy 
37 19 56 
66.1% 33.9% 100.0% 
 
Table 3: Distribution of the Duration of the traumatic 
brain injury in the study groups. 
 
 Group of Treatment  Mean 
Std. 
Deviation 
Duration of 
trauma 
(in hours) 
Magnesium 
Supplement therapy 
4.98 2.32 
Placebo therapy 5.05 2.48 
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Duration Since Injury 
Table 3 shows mean duration passed 
between hospital presentation and traumatic 
brain injury was 4.98 hours in the 
magnesium sulfate group while it was 5.05 
in the placebo group. 
 
Statistical Analysis 
After applying t test it was evaluated that 
mean Glasgow outcome score was 3.57 ± 
1.33 in the magnesium sulfate group while 
2.78 ± 1.23 in the placebo group and this 
difference was statistically significant 
(Table 4). 
 
Stratification of Data 
Data was stratified for the impact of the age, 
gender and duration elapsed between trauma 
and presentation of patients and presented in 
tables 5 – 7. 
 Table 5 describes the stratification of 
the Glasgow outcome score in the treatment 
groups with respect to age. Glasgow 
outcome score in patient with age < 30 years 
was 3.65 ± 1.20 in magnesium sulfate group 
vs. 2.65 ± 1.19 in the placebo group. GOS, 
in patients with age > 30 years was 3.45 ± 
1.41 in magnesium sulfate group vs. 2.93 ± 
1.28 in the placebo group. 
 Table 6 shows the stratification of the 
Glasgow outcome score in the treatment 
groups with respect to gender. Glasgow 
outcome score in male patients was 3.48 ± 
1.30 in magnesium sulfate group vs. 2.73 ± 
1.28 in the placebo group. GOS in female 
patients was 3.73 ± 1.14 in magnesium 
sulfate group vs. 2.88 ± 1.40 in the placebo 
group. 
 Table 7 shows the stratification of the 
Glasgow Outcome score in the treatment 
groups with respect to duration of Disease. 
Glasgow outcome score in patient after 1 – 6 
months post TBI was 3.50±1.23 in 
magnesium sulfate group vs. 2.60 ± 1.26 in 
the placebo group. GOS in patients > 6 
hours of TBI was 3.75 ± 1.14 in magnesium 
sulfate group vs. 2.88 ± 1.40 in the placebo 
group. 
 CT scans are shown in figures. Figure 1 
 
Table 4: Comparison of Mean Glasgow Outcome Score in the Both 
Study groups. 
 
 Group of treatment Mean 
Std. 
Deviation 
P-value 
 Glasgow Outcome  
 Score 
 Magnesium 
 Supplement therapy 
3.57 1.23 
0.002 
 Placebo therapy 2.78 1.33 
 
Table 5: Stratification of the Glasgow Outcome score in the treatment 
groups with Respect to Age. 
 
Age  Group of Treatment 
Glasgow Outcome 
Score 
P-value 
Mean 
Std. 
Deviation 
18 – 30  
years  
 Magnesium Supplement therapy 3.65 1.20 
0.002 
 Placebo therapy 2.65 1.19 
>30  
years  
 Magnesium Supplement therapy 3.45 1.41 
0.16 
 Placebo therapy 2.93 1.28 
 
Table 6: Stratification of the Glasgow Outcome score in the treatment 
groups with Respect to Gender. 
 
Gender Group of Treatment 
Glasgow Outcome 
Score P-
value 
Mean 
Std. 
Deviation 
Male 
Magnesium Supplement therapy 3.48 1.30 
0.01 
Placebo therapy 2.73 1.28 
Female 
Magnesium Supplement therapy 3.73 1.14 
0.05 
Placebo therapy 2.88 1.40 
 
Table 7: Stratification of the Glasgow Outcome score in the treatment 
groups with Respect to Duration of Disease. 
 
Duration 
of Disease 
Group of Treatment 
Glasgow Outcome 
Score 
P-value 
Mean 
Std. 
Deviation 
1 – 6 
months 
Magnesium Supplement therapy 3.50 1.23 
0.002 
Placebo therapy 2.60 1.26 
> 6 hours 
Magnesium Supplement therapy 3.75 1.17 
0.39 
Placebo therapy 3.22 1.48 
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shows various types of traumatic brain injuries 
(extradural hematoma, contusion, diffuse axonal 
injury, acute subdural hematoma, subarachnoid 
hemorrhage). Figure 2 represents a CT scan of right 
sided acute subdural hematoma with significant 
midline shift. Figure 3 shows a CT scan of diffuse 
axonal injury. 
 
 
 
Fig. 1: CT scan showing various types of traumatic brain 
injury (extradural hematoma, contusion, diffuse 
axonal injury, acute subdural hematoma, and 
subarachnoid hemorrhage). 
 
 
 
Fig. 2:  CT scan of Acute Subdural Hematoma. 
 
 
Fig. 3:  CT scan of Diffuse Axonal Injury. 
 
DISCUSSION 
This study gives data on the efficacy of magnesium 
sulfate and its use in the patients with brain injury. 
More studies should be conducted to see the effects, 
efficacy, safety and increase in magnesium levels in 
the CSF with this therapy. Most studies have been 
done on the animals so insufficient data is available on 
human trials which means there is a need for more 
human clinical trials with magnesium therapy. One 
study (randomized controlled trial) gives the data 
regarding the effects of five-day intravenous infusion 
of magnesium sulfate therapy on the Glasgow coma 
scale and Glasgow outcome score and showed the 
comparison between the placebo and magnesium 
sulfate treatment groups in patients with brain trauma. 
 In a study done by Ling Zhao et al, (2016) there 
was significant improvement in GOS in MST 
(magnesium sulfate therapy) group as compared to 
placebo group. The mean GOS score was significantly 
higher in the MST group at discharge and 1 month 
after discharge consistent with the results of the 
current study.
8
 
 In spite of many clinical trials done on rodent 
animals which showed the efficacy of magnesium 
sulfate therapy and improvement in clinical outcome 
in patients with traumatic brain injury; in a recent 
study magnesium sulphate therapy didn’t show any 
efficacy in improvement of clinical outcome.
15
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 Magnesium plasma levels were corrected in all 
patients, those in magnesium treatment group received 
additional doses of magnesium at least double 
magnesium plasma levels as compared to placebo. 
McKee et al, (2005) mentioned that magnesium didn’t 
show any improvement in the clinical outcome at 
double plasma levels rather had serious side effects in 
many patients as compared to placebo group. The dose 
response of magnesium as seen in the preclinical 
studies, brought into attention that in patients with 
TBI, intravenous magnesium can only slightly increase 
the CSF magnesium levels.
16-17
 
 It’s critical to know that this slight increase in CSF 
magnesium levels will be sufficient to increase the 
cellular free magnesium concentration which is 
mandatory for its neuroprotective properties.
17
 
 Habgood et al, (2007) reported that magnesium 
sulfate levels in the CNS depend on the integrity of 
blood brain barrier. In studies done on rats, brain 
injury led to more disruption of blood brain barrier 
which resulted in excessive magnesium entry into the 
cells for 24 hours, this doesn’t happen in human CNS 
after trauma.
18-19-20
 
 It is therefore expected that magnesium levels in 
the cells may not be as in the clinical trials, in this case 
the peripheral effects of magnesium may be more than 
the central and will affect the vitals of the patient 
including the blood pressure and cerebral blood flow. 
 It is necessary to have more clear knowledge about 
the entry of magnesium into the human central 
nervous system to have better results from the therapy. 
 Neuronal cell death after brain injury has multiple 
factors that are why combination therapy is 
recommended in many reports. Combination therapies 
target more than one factor, have gained attention over 
the period of time and have more efficacy. Different 
combination therapies have been studied until now in 
patients with brain trauma and ischemia like 
magnesium in combination with growth factors, 
glutamate antagonists, vitamin B, immunosuppressant, 
hypothermia, antioxidants.  Studies have shown 
various results in preclinical trials, among them a 
combination of magnesium and hypothermia had 
better results. Further clinical studies are 
recommended to see the efficacy of combined 
magnesium and hypothermia therapy in patients with 
brain ischemia.
21-22-23
 
 According to the meta-analysis, mortality was 
almost same between the groups. In a study done by Li 
et al, (2015)
24
 the Glasgow outcome score was higher 
in the magnesium sulphate treatment group as 
compared to the placebo group, but the significance 
was marginal; post treatment change in the Glasgow 
outcome score was significantly higher in the 
magnesium sulphate treatment group as compared to 
placebo.
24
 Magnesium treatment group showed 
significant improvement in GCS after two months post 
trauma (p = 0.03). Motor functioning scores of patients 
in the MgSO4 group were higher than those in the 
control group but this was not statistically significant 
(p = 0.51). The study shows that magnesium sulphate 
treatment has neuroprotective effects in the CNS in 
patients with severe diffuse axonal injury.
25
 The results 
of these studies were in consistent with the results of 
the current study. 
 In a study done by Lyons et al, (2018) there was 
no major improvement in the GOS in the treatment 
group as compared to the placebo, although, GCS 
showed a significant improvement in the treatment 
group which was contrary to this study.
26
Maselet al, 
(2010) is suggested that the magnesium sulphate 
shows the tendency to significantly improve the 
Glasgow Outcome Scale and Glasgow Coma Scale 
score, this is very positive result for traumatic brain 
injury therapy.
27
 
 From the current research it’s quite obvious that 
the use of magnesium sulphate therapy is beneficial 
for the patients with traumatic brain injury, it improves 
the Glasgow Outcome Scale and the Glasgow coma 
score which is consistent with other studies. More 
studies need to be done to come to a conclusion that in 
which type of brain trauma, the magnesium sulphate 
therapy would have the better outcome. 
 
CONCLUSION 
It was observed that the use of the Magnesium 
sulphate in the patients presenting with the traumatic 
brain injury must be emphasized and should be used as 
an add-on therapy along with the standard treatment 
protocols so that patients could be recovered from the 
injury. It is further recommended that more studies 
should be carried out on the trauma patients. 
Generalizability of the results of this study depends on 
the future studies. 
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